Member Info for Moneymunch

Eric did say in his recent iterview they had "several " non-dilutive grant applications that were looking very promising. We've had confirmation of the $4m Wallonia grant and so every chance news of another one next. Gla holders, the current bargain low offers tremendous UPside potential, especially commensurate to the lowly market cap of £6.29 and not far off £5m cash in the bank. Plenty more potential positive newsflow stacking UP!!! :-)

Exciting times indeed, and looks like Genflow could be in the mix given their cutting edge science and the huge potential of longevity R & D was highlighted in Parliament in July 2024. Gla ;-)

Britain can become the global leader in longevity science, Lord Lebedev has told Parliament.

23/7/24

Longevity research ‘can unlock huge benefits’ for Britain as it tackles an ageing population

‘As life expectancy has increased, the proportion of time spent in good health is going down. We must urgently develop a new approach to medicine’ - Lord Lebedev

He stressed that longevity research could “unlock huge benefits” for the UK as it faces the challenges of an ageing population. “Our country faces a medical crisis,” he said. “As life expectancy has increased, the proportion of time spent in good health is going down. We must urgently develop a new approach to medicine.”

......

“The discovery of the 12 hallmarks of ageing, including the loss of stem cells and metabolic dysregulation, are central to our understanding of what drives age-related disease,” the crossbench peer told the Upper House.

“A groundbreaking new theory suggests ageing is driven by the loss of vital regulatory information within our cells, rather than primarily accumulating damage over time. Through epigenetic reprogramming, we could potentially reset our body’s tissues to a more functional state. Scientific studies have already reversed vision loss in mice and human trials are set to begin next year.”

The peer highlighted drugs being developed to reverse aspects of ageing.

“Cutting-edge breakthroughs like these, driven by labs right here in the UK, are informing how we tackle the underlying factors behind ageing, rather than just tackling symptoms,” he added. He stressed further: “We stand at the precipice of a medical revolution, catalysed by medical monitoring devices, genomics, and our understanding of what drives ageing.

“Britain can become the global leader in longevity science, and capturing this beachhead will benefit us both socially and economically.” He emphasised that the science is now “moving as rapidly as the AI revolution and will be similarly, if not more impactful”.

hTtps://www.standard.co.uk/news/politics/longevity-research-benefits-population-lord-lebedev-speech-b1172354.html

In Eric we trust!!!🤩👍🤞

Grabbed around 650k shares this morning at this rockbottom bargain low, one trade for 365k plus shares yet to be listed. Genflow has plenty of cash going forward and their cutting edge science offers exponential UPside potential and there's plenty of potential stellar newsflow to look forward in the coming weeks and months to add significant value. Gla holders;-)

Tomorrow Porter, and amazed to see the sp so low considering Genflow's expected newsflow and how much cash they have in the bank and amazed to see pi's part with their shares so cheaply......A no-brainer and absolute steel imho and for once i will be hoping there's no news 7am tomorrow to take full advantage. Gl :-)

Shh Porter, everything is progressing as planned and Genflow's journey from small cap to mid cap lies ahead. I've funds clearing for a top UP or two on Wednesday and will be happy if it stays bargain basement until then...No news Eric until Thursday please if you've got anything UP you sleeve!!! Gla :-)))

Along with Genflow's collaborative partners, cutting edge science will prevail Porter, and so well worth keeping tabs on Exothera on Linkedin, who are making strides and appear very excited going forward, as well as Exo Biologics for Sirt6's Exsome AVV Gene delivery. All bodes well for a fully funded Genflow. Gl ;-)

30/9/24

Exosome-mRNA project with EXO Biologics - which aims to deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, potentially leading to groundbreaking treatments for both diseases.

........

EXO Biologics

2,839 followers

1mo

🚀 News from Our Subsidiary, ExoXpert!

We proudly celebrate ExoXpert's latest achievement: the Belgian Authorities have officially inspected their new facilities in LégiaPark for GMP certification! 🌟

This crucial step reflects ExoXpert's unwavering commitment to upholding the highest quality, safety, and compliance standards as an exosome-specialized CDMO. Their dedication to empowering exosome product developers and making breakthrough therapies more accessible is inspiring!

At EXO Biologics, we share the same vision of advancing the potential of exosomes as therapies and drug delivery vehicles. This milestone underscores our collective effort to provide top-tier support to our partners.

🔗 Follow ExoXpert’s journey as they continue to lead the way in exosome manufacturing and innovation.

ExoXpert

711 followers

1mo

📢 Committed to Quality & Compliance

We are thrilled to announce that we’ve officially been inspected by FAMHP for GMP (Good Manufacturing Practices) certification! 🌟

As an exosome-specialized CDMO, this is an essential step in our journey to ensure the highest quality, safety, and compliance standards in everything we do. Our team is fully committed to delivering products that meet global regulatory standards, reinforcing our commitment to supporting exosome product developers.

At ExoXpert, we believe in the potential of exosomes as therapeutics and as vehicles for drug administration. By pursuing GMP certification, we’re making our state-of-the-art production platform even more accessible to clients and partners.

Stay tuned for updates as we work through this significant milestone!

Check out how we accelerate EV clinical trials for our partners:

https://lnkd.in/evu8K9xQ

He's posted that ramp on over 30 threads on Lse.👎

Good Morning Porter, in response to your comments on Eric's interiew, i'm fairly certain that Exothera will likely be the preferred manufacturer given the ongoing collaboration and leading members of the Wallonia biotech hub and have also received substantial grant funding to adance their cutting edge science and technology. Exciting times ahead, despite the current sp performance. Gl ;-)

30/9/4 Half Year Results

Additionally, we have initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP). We are also in the process of selecting Contract Research Organizations (CROs) to conduct our upcoming dog clinical trial, aimed at studying our simplified Nake DNA version of our Centenarian SIRT6 drug candidate, GF-1004. We will provide updates in relation to our veterinary study in due course.

...........

Exothera

13,026 followers

3mo

Exciting Collaboration Alert!

We're thrilled to partner with Genflow Biosciences (LON:GENF) (OTCQB:GENFF) to advance their preclinical efforts in combating MASH, leveraging our cutting-edge exoREADY platform! With our unparalleled expertise in bioprocessing and GMP services for AAV, we're ready to accelerate breakthroughs in biotherapeutics.

Let's innovate together! 🌟

🔗 https://lnkd.in/eBFJhxxD

#Biotech #AAV #Genflow #MASH #Bioprocessing #GMP #Innovation #Healthcare

..........

Exothera

13,026 followers

2mo

Adeno-associated viruses (AAVs) have emerged as a leading vector for gene therapy applications, offering benefits such as target tissue specificity and anon-replicating nature.

As the number of AAV clinical trials rapidly increases, robust manufacturing processes are crucial to ensure product quality and safety.

At Exothera, we developed a a standardized manufacturing process based on Quality-by-Design principles.

Our approach ensures sustainable commercial-scale yields while meeting stringent Chemistry, Manufacturing and Controls (CMC) requirements.

Get our insight poster below to learn more about how our ExoReady process is designed to support the manufacture of your AAV therapy.

https://lnkd.in/e6UQnnG7

#GeneTherapy #CellTherapy

No debt, no doubt!!! :-)))

This will move big in the coming days with the short term profit takers mopped UP on the cheap....more potential positive news stacking UP...hold on tight and enjoy the ride. Genflow are fully cashed with no doubt for the foreseeable. ;-)

Brilliant news Porter, and just the start of Genflow's stellar UPside journey!!! Gl ;-)

22 October 2024

Genflow Biosciences Plc

Genflow Secures €4 Million Non-Dilutive Financial Support from Wallonia Region for GF-1002 Development

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that it has received official confirmation of €4,026,525 in non-dilutive financial support from the Wallonia region. The funds will support the ongoing development of Genflow's lead gene therapy, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe and progressive liver disease.

The financial support comprises a €1,218,349.44 non-reimbursable research grant, covering 70% of the Company's research costs, and a €2,808,175.92 recoverable advance, repayable to the Wallonia region upon commercialisation GF-1002 for use in treating MASH, funding 55% of the Company's development costs. This funding, when received, is expected to cover three years of Genflow's development program for GF-1002,with the first installment being received as working capital. The Company is committed to securing the necessary funding to cover its share of the project over the next three years.

The securing of such funding marks a significant milestone for Genflow and will enable the Company to accelerate the clinical progress of GF-1002, which represents a novel approach to treating MASH, a condition with limited treatment options. The Wallonia region's financial support highlights the growing recognition of Genflow's innovative work in gene therapy.

Dr. Eric Leire, CEO of Genflow, commented: "We are delighted to receive this substantial financial backing from the Wallonia region as it is an important validation of our research and development efforts. It will allow us to further the development of GF-1002 and strengthen our position at the forefront of gene therapy innovation for MASH treatment. We would like to sincerely thank the Wallonia region for its support."

Further updates on the progress of GF-1002 will be provided in due course.

View organization page for BioWin, graphic

BioWin

12,891 followers

9h

What is the Belgian recipe for an innovative ecosystem in advanced therapies? Read this interesting Paper from Deloitte, developed with input from BioWin and MEDVIA. It addresses the challenges in commercialising advanced therapies and highlights Belgium’s potential to become a biomanufacturing hub in Europe, thanks to its strong logistics, academic expertise, and infrastructure.

👉 Download the full report: https://lnkd.in/eKrAT5UP

View organization page for BioWin, graphic

BioWin

12,891 followers

4d

When innovators get together, good things happen. That was the case last Tuesday at our Advanced Therapies in Belgium event. We were inspired by the incredible industry leaders looking to advance the development and accessibility of next-generation therapies for patients. Collaboration between academia, industry, government, and patient associations is crucial to bringing these advanced therapies to market. Belgium has all the ingredients to become a global leader in this field, but we must work together!

Key event highlights:

250+ ATMP experts from Belgium and key international stakeholders

175+ organisations, including startups, hospitals, universities & companies.

420+ partnering requests, highlighting interest in collaborative innovation.

280+ scheduled meetings, with plenty of potential partnerships ahead.

Thank you to our sponsors, exhibitors, speakers, pitchers, supporters and participants! And a huge thank you to all of the strategic sponsors who made the event possible, including: UCB, Thermo Fisher Scientific, Aseptic Technologies, Johnson & Johnson, Deloitte, Wallonia Export & Investment Agency

Looks like someone is loading UP on the cheap...news at anytime!!! Gla holders:-)

In Eric we trust!!! Gl ;-)

Lol, you're going to have a long wait then with any luck, news of more non-dilutive grant cash coming "very soon"!!! Gla holders ;-)

Genflow's recent Sirt6 Research publication could be of great interest to Lilly's UK investment plans. Gla :-)

20/7/24

Conclusions: SIRT6 N308K/A313S overexpression in mature adipocytes ameliorated glucose sensitivity and impacted sympathetic innervation signaling. These findings highlight the importance of targeting SIRT6 enzymatic activities to regulate the co-morbidities associated with obesity.

htTps://pubmed.ncbi.nlm.nih.gov/39033117/

Funding

This work was supported by GenFlow Bioscience, by the European Commission Horizon 2020 Framework Program (Project 856871”TRANSTEM, to MV) and by grants from the US national Institute of Health, Impetus Grants and Michael Antonov Foundation (to VG).

Lilly to Invest $364 Million in UK Biotech, Obesity Research

Drugmaker will also study obesity medication rollout in UK

Labour government has tried to attract foreign investment

The UK has aimed to position itself as a life-sciences superpower.

14 October 2024

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of the impact of its blockbuster drugs for diabetes and obesity on the use of health-care resources.

The Indianapolis-based drugmaker’s investment includes as much as £204 million to establish a Lilly Gateway Labs location in the UK, according to an emailed statement Monday, giving early-stage biotechs access to Lilly’s expertise, lab space and potential financial investment.

hTtps://www.bloomberg.com/news/articles/2024-10-14/lilly-to-invest-364-million-in-uk-biotech-obesity-research?srnd=all&embedded-checkout=true